BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P decreased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) by 12.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,878 shares of the biotechnology company’s stock after selling 7,060 shares during the period. Martingale Asset Management L P’s holdings in BioMarin Pharmaceutical were worth $3,576,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMRN. Tidal Investments LLC raised its position in BioMarin Pharmaceutical by 65.5% during the first quarter. Tidal Investments LLC now owns 17,447 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 6,906 shares during the last quarter. DNB Asset Management AS raised its position in BioMarin Pharmaceutical by 17.7% during the second quarter. DNB Asset Management AS now owns 1,021,054 shares of the biotechnology company’s stock worth $84,063,000 after acquiring an additional 153,867 shares during the last quarter. Quent Capital LLC raised its position in BioMarin Pharmaceutical by 58.9% during the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 145 shares during the last quarter. CWM LLC raised its position in BioMarin Pharmaceutical by 68.5% during the second quarter. CWM LLC now owns 2,398 shares of the biotechnology company’s stock worth $197,000 after acquiring an additional 975 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC raised its position in BioMarin Pharmaceutical by 2.3% during the second quarter. Inspirion Wealth Advisors LLC now owns 13,458 shares of the biotechnology company’s stock worth $1,108,000 after acquiring an additional 304 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the transaction, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.85% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Trading Up 0.9 %

Shares of BMRN stock opened at $66.03 on Friday. The stock has a market cap of $12.58 billion, a price-to-earnings ratio of 39.54, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a fifty-two week low of $61.15 and a fifty-two week high of $99.56. The firm’s 50 day moving average price is $67.72 and its two-hundred day moving average price is $77.91.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The business had revenue of $746.00 million for the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. On average, analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.49 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on BMRN. Scotiabank cut their target price on shares of BioMarin Pharmaceutical from $95.00 to $78.00 and set a “sector perform” rating for the company in a research report on Tuesday, September 17th. Barclays lowered their price target on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a report on Friday, October 4th. Truist Financial lowered their price target on shares of BioMarin Pharmaceutical from $118.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Stifel Nicolaus lowered their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Get Our Latest Research Report on BioMarin Pharmaceutical

BioMarin Pharmaceutical Profile

(Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Recommended Stories

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.